Clinical trials: Acne Inversa
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week…
- Trial name
- STOP-HS1 (NCT05620823)
- Testing
- Povorcitinib
- Where
- 104 sites in United States, Austria and 10 more
- Volunteers
- 608 people
- Sponsor
- Incyte Corporation